Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageOur portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb. The following is a brief description of the Company’s segments: For additional discussion of our reportable segments, see the discussion in Item 1. “Business — Segment Information” and Note 23, “SEGMENT INFORMATION” to our audited Consolidated Financial Statements.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q4 2024 · $2.56BThe company’s own SEC segment disclosure.
- United States and Puerto Rico$1.54B60%
- Other Countries$292.0M11%
- China$145.0M6%
- Canada$109.0M4%
- Poland$94.0M4%
- Mexico$67.0M3%
- Other (8)$312.0M12%
Bausch Health Companies Inc. (BHC) reported revenue of $2.52B in Q1 2026 (quarter ended Mar 31, 2026), up 12% from the same quarter a year earlier. That came with net loss of $1.43B. For the full year FY2025, revenue was $10.3B (+6.7% year on year) and net income $120M. Its largest region in Q4 2024 (quarter ended Dec 31, 2024) was United Statesand Puerto Rico at $1.54B, 60% of the disclosed total, well ahead of Other Countries at 11%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #24 of 29 by Smart Score